
DNA is in our blood
Natera™ is a global leader in cell-free DNA (cfDNA) testing with a focus on women’s health, oncology, and organ health. Our mission is to change the management of disease worldwide by using information gained from a simple blood draw to proactively inform treatment.


Next-generation cell-free DNA testing
Through our next-generation, cell-free DNA (cfDNA) technology platform, we’ve pioneered noninvasive blood-based testing in the fields of women’s health, oncology, and organ health.
Focused on experience and support
At Natera, we’re building an entirely new way to manage genetic testing: in the cloud. We’ve made it possible to virtually order tests, schedule mobile blood draws, access test results, and consult with genetic counselors — all with the click of a button. Our global footprint spans 90 countries worldwide, putting DNA testing within reach.

Our mission is personal
Applying clinical expertise, leading-edge technology and operational excellence to change the management of disease worldwide



Natera was born from a deeply personal desire to change the way disease was managed.

Matthew Rabinowitz
Founder of Natera
Since its founding, Natera has pushed the boundaries of testing management with a proven track record of scientific excellence and innovation.
2004 | ![]() |
Natera, Inc. is founded by Matthew Rabinowitz, Ph.D. and Jonathan Sheena, M. Eng |
---|---|---|
2009 | Spectrum preimplantation genetic test launches | |
2010 | Anora miscarriage test (POC) launches | |
2012 | Horizon advanced carrier screening test launches | |
2013 | Panorama next-generation NIPT launches | |
2015 | ![]() |
Natera, Inc. holds Initial Public Offering (IPO) |
Aug 2016 | ![]() |
Natera and USCF collaborate on a study evaluating the use of donor-derived cell-free DNA (dd-cfDNA) in kidney transplant patients |
2017 | Vistara single-gene NIPT launches | |
2017 | Signatera molecular residual disease (MRD) test launches (Research Use Only) | |
Apr 2017 | Study published in Nature shows early relapse detection in lung cancer using Natera’s circulating tumor DNA (ctDNA) technology | |
Aug 2018 | ![]() |
Natera and Fox Chase Cancer Center collaborate on kidney cancer study using the Signatera RUO test |
Aug 2018 | Signatera RUO Test shown to detect molecular residual disease up to 2 years prior to clinical relapse and to predict treatment response in breast cancer | |
Jan 2019 | ![]() |
Steve Chapman appointed CEO |
2019 | Signatera CLIA test launches | |
May 2019 | ![]() |
FDA grants breakthrough device designation to Natera’s Signatera test |
Aug 2019 | Panorama NIPT achieves 2 million test milestone | |
2019 | Prospera dd-cfDNA transplant assessment test launches | |
2020 | Empower hereditary cancer test launches | |
Jun 2020 | ![]() |
Natera expands lab footprint with a facility in Austin, Texas |
2020 | Renasight kidney gene panel launches | |
Aug 2020 | Publication in Nature Cancer shows Signatera’s ability to evaluate tumor response to immunotherapy |